Product Program year 2020 Source: CMS Open Payments

Injectafer

Drug Anemia

NDC 0517-0650-01

Open in the dashboard

General payments

$2,561,711

38,996 payments

Research payments

$18,027,684

1,469 payments

Through program year 2020, $2,561,711 in general payments and $18,027,684 in research payments were reported against Injectafer (Anemia).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2020 General $751,122 16,148
2020 Research $8,985,204 713
2019 General $1,810,589 22,848
2019 Research $9,042,480 756

Breakdown

Who paid General payments · program years 2019–2020
  1. Daiichi Sankyo Inc. $2,289,389 38,926 payments
  2. American Regent $272,323 70 payments
Top recipients General payments · program year 2020
  1. Kiran Kancharla Hematology & Oncology · Irving, TX $36,920 5% · 61 payments
  2. Martin Dietrich Hematology & Oncology · Rockledge, FL $34,121 5% · 35 payments
  3. Chandar Bhimani Hematology & Oncology · Conyers, GA $32,464 4% · 21 payments
  4. Ahmed Sawas Hematology · New York, NY $31,454 4% · 26 payments
  5. Rahul Dixit Gastroenterology · Santa Monica, CA $22,907 3% · 33 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Hematology & Oncology Internal Medicine $216,986 29% · 644 practitioners
  2. Obstetrics & Gynecology $112,498 15% · 1,858 practitioners
  3. Gastroenterology Internal Medicine $71,014 10% · 1,120 practitioners
  4. Internal Medicine $61,085 8% · 1,278 practitioners
  5. Family Medicine $56,103 8% · 1,632 practitioners

The top 5 of 98 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. California $135,659 18% · 626 recipients
  2. Texas $94,118 13% · 515 recipients
  3. New York $64,123 9% · 566 recipients
  4. Florida $61,107 8% · 643 recipients
  5. Pennsylvania $49,190 7% · 442 recipients

The top 5 of 53 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to INJECTAFER
Billing code Providers Services Paid by Medicare
Injection, ferric carboxymaltose, 1 mg J1439 1,032 38,342,118 $33,249,722

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

38,996 general · 1,469 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record